Imperial Oil Limited Common Stock vs Novo Nordisk A/S — how do they compare? Imperial Oil Limited Common Stock trades at $129.6 (market cap $62.22B), while Novo Nordisk A/S trades at $38.7 (market cap $169.08B). The key difference: Novo Nordisk A/S is far larger — about 2.7× Imperial Oil Limited Common Stock's market cap, and Novo Nordisk A/S pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| IMO | NVO | |
|---|---|---|
Market Cap | $62.22B | $169.08B |
Volume | 560,544 | 9,259,152 |
Sector | Energy | Health |
52-Week High | $138.33 | $63.98 |
52-Week Low | $83.72 | $35.29 |
Enterprise Value | $63.13B | $183.28B |
Dividend Yield | 1.9% | 4.72% |
Typical Hold Time | — | 116 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novo Nordisk (NVO) trades at $38.12, down 1.19% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.96, beating expectations by 17%, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 9.67 and ROE of 59.82%, while recent news highlights pipeline expansion through $4 billion in licensing deals and progress on oral Wegovy formulations.
The stock presents a compelling value opportunity with strong profitability and growth prospects in obesity/diabetes markets, though technical weakness and competitive pressure from Eli Lilly create near-term headwinds. Analyst consensus remains bullish with $42.33 price target representing 11% upside potential from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →